
Ten million needed on LA-PrEP to achieve significant effect on worldwide HIV epidemic


943

Dr Samuel Cross [1], Dr Francois Venter[2], Dr Andrew Hill [3] for the International Treatment Preparedness Coalition (ITPC)
[1]NHS Greater Glasgow and Clyde, Glasgow, UK, [2]University of Witwatersrand, Johannesburg, South Africa, [3]Department of Translational Medicine, University of Liverpool, Liverpool, UK

BACKGROUND


- UNAIDS projects global HIV incidence rising from **1.3m (2024)** to **1.45m (2030)** with PrEP coverage decline due to funding cuts
- Long-acting PrEP (CAB-LA, LEN) is superior to oral TDF/FTC
- UNAIDS goal to reach <300,000 new acquisitions by 2030
- Major price disparity:
  - **CAB-LA:** $22,000/year (US) vs $180/year (SSA)
  - **LEN:** $28,000/year (US) vs $100/year (LMICs)
  - Estimated production cost ≈ **$25/year**







METHODS

- UNAIDS Spectrum modelling used to **estimate new acquisitions** in countries **included vs excluded** from **voluntary licenses**
- **Global LA PrEP coverage estimates** using:
  - Global sales data from pharmaceutical filings (sales data for LEN estimated from grouped revenue)
  - Efficacy estimates from HPTN (CAB-LA) and PURPOSE (LEN)
  - PURPOSE background incidence (2.4%)
  - Assumed 30% discount on US list price of LEN and CAB-LA
  - LMIC CAB-LA price $180/year (PEPFAR)






1,860 total HIV infections prevented in 2025



Voluntary license for LA-PrEP: LMICs included and excluded

240,000 new HIV acquisitions per year in LMICs not covered in VLs for LA-PrEP



RESULTS

2025 CAB-LA uptake:

- **US:** $432m → 28,000 users → ~700 HIV acquisitions prevented = **1.8% of 39,000 US infections**
- **LMICs:** $7m → 35,000 users → ~970 HIV acquisitions prevented = **0.1% of 950,000 acquisitions in LMICS eligible for access via VLs**
- **EU: $0**


2025 LEN uptake:

- **US:** $148m → 7,600 users → ~190 infections prevented = **0.4% of 39,000 US acquisitions**
- **LMICs: $0**
- **EU: $0**

LEN scale-up:

- Current supplies from Gilead for 2 million users by 2027 → ~25,000 infections prevented/year
- **10 million users → 250,000 acquisitions prevented/year based on PURPOSE trials efficacy and background risk.**

HIV acquisitions: reduced PrEP coverage (UNAIDS) vs. 10 million people on LA -PrEP



CONCLUSIONS

- We have a rare chance to end the HIV epidemic but **only** if **LA-PrEP is affordable**
- Current LA-PrEP rollout will have **minimal epidemiologic impact**
- US/EU prices block meaningful scale; HIC pricing must fall **< $1000/year**
- **≥10 million users in LMICs** required for significant global impact

This work was funded by the International Treatment Preparedness Coalition (ITPC)

Email contact: sd.cross@hotmail.com